Zotizalkib (TPX-0131) is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK ( IC 50 of 1.4 nM) and ALK-resistant mutation , e.g. G1202R ( IC 50 of 0.3 nM), L1196M ( IC 50 of 0.3 nM). Zotizalkib has strong antitumor activities.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.